This educational activity is supported by educational grants from the following companies:
Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Management of Multiple Myeloma Patients Treated With Immunotherapy
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The University of Arizona Cancer Center
In November 2015, the FDA approved three new therapies for multiple myeloma: daratumumab, ixazomib, and elotuzumab. The rapid-fire rate of new drug approvals for all cancer types makes it challenging for advanced practitioners to stay informed about clinical trial data, new therapies, new indications, mechanisms of action, and potential adverse reactions. This activity will provide an invaluable overview of new immunotherapies for patients with multiple myeloma.
Management of Newly Diagnosed Multiple Myeloma Patients
Relapsed or Refractory Multiple Myeloma
Adjunctive and Supportive Care in Multiple Myeloma
Risk Stratification in Multiple Myeloma
How do IMIDs work?
What does an advanced practitioner need to know to create an optimal treatment regimen for the individual patient and explain the benefits and risks of the available choice to patients?
Briefly define low-risk vs high risk patient and how risk stratification influences treatment decisions.
What are the toxicities associated with the agents used for multiple myeloma?
What are some monitoring parameters for toxicities to establish?
How can I increase patient adherence to treatment regimens for multiple myeloma?
Bone Marrow Biopsy Demonstration Video